Structure Therapeutics Inc. American Depositary Shares (GPCR · NASDAQ)

Structure Therapeutics (GPCR) has fallen sharply, down 41.6% over the past month and 49.8% over three months to $27.67, leaving shares 70.5% below their 52-week high with an RSI of 16. The clinical-stage biotech generated no revenue in the trailing twelve months and posted a quarterly net loss of $106.2 million as of June 30, though it holds $272.6 million in cash against just $6.2 million of debt and a current ratio of 20.75. The company missed analyst EPS estimates in three of its last four quarters, including a June-quarter loss of $0.49 versus a $0.39 estimate. The analyst target stands at $105.78, and recent commentary has focused on the company's cash runway to fund ongoing operations.